GLOBAL SOUTH KOREA DIGITAL THERAPEUTICS MARKET (2026 - 2030)
The South Korea Digital Therapeutics Market was valued at approximately USD 163 Million. It is projected to grow at a CAGR of around 19% during the forecast period of 2026–2030, reaching an estimated USD 388.98 Million by 2030.
The South Korean digital therapeutics market consists of software applications that use evidence-based digital therapeutic interventions to prevent, manage, and treat medical conditions that have been clinically proven to be effective. These solutions are increasingly being incorporated into patient care pathways, and they are being applied to complement or even, in some cases, replace traditional treatment modalities. The market includes therapeutic software that's made available via digital channels and offered to help manage chronic diseases, behavioral health, neurological diseases, and other medically recognized uses. It doesn’t apply to general health apps, fitness trackers with no therapeutic claims, teleconsultation-only services, or hardware products that aren't directly used for therapy.
The market is no longer a technology-driven concept; it's a healthcare delivery market where clinical outcomes, patient engagement, and measurable treatment effectiveness are the things that matter in the market. The need for scalable healthcare solutions and increasing regulatory clarity and awareness among physicians has led to the wider adoption across various disease areas. There is a greater focus on real-world evidence generation and better adherence rates with the ability to show long-term value in everyday clinical practice for healthcare providers and developers.
The market now offers decision makers more opportunities besides product innovation. Reimbursement readiness, integration into the current healthcare workflow, and the ability to show long-term patient results are now becoming key aspects of commercial success. As South Korea's digital health landscape continues to transform, clinical validation, adoption potential, and payment models are emerging as key considerations in the competitive positioning and long-term growth of organizations making investments, partnerships, or expansion plans.
Key Market Insights
Research Methodology
Scope & Definitions
Evidence Collection (Primary + Secondary)
Triangulation & Validation
Presentation & Auditability
South Korea Digital Therapeutics Market Drivers
Scalable digital treatment delivery is top of mind for healthcare providers.
In South Korea, health organizations are becoming more interested in models of treatment that rely on technology to enable treatment outside the clinical environment. Digital therapeutics enable a patients' continuous engagement, automated intervention delivery and structured outcome monitoring, without the need for frequent face-to-face visits. This shift is part of a wider modernization of healthcare that aims to enhance the efficiency of healthcare processes, increase access to healthcare services, and facilitate long-term disease management.
Therapeutic data integration is on the fast track with connected health ecosystems.
The rollout of connected healthcare infrastructure is creating conditions ripe for digital therapeutics deployment. More modern treatment settings are increasingly dependent on interoperable platforms that facilitate the interoperability and transfer of patient data between patients, clinicians, and care management systems. This transformation is beneficial for digital therapeutics, which enable automated monitoring, tailored interventions, and immediate clinical insights, fostering seamless treatment adherence and informed clinical choices.
Treatment plans are changing with a greater focus on individualized care models.
There is a growing focus on personalized treatment strategies that align with patients' behaviors, adherence, and clinical outcomes. Digital therapeutics offer the capacity of software-based interventions and continuous monitoring, thereby improving care pathways. These solutions are becoming more important in scaling personalized care as providers strive for more targeted and outcome-driven treatment models.
South Korea Digital Therapeutics Market Restraints
Even with the clinical interest, the market is plagued with reimbursement uncertainty, time-consuming evidence generation needs, and physician take-up variability. However, many providers are still hesitant to implement software-based therapies as a part of their normal practice. Greater concerns around data privacy, adherence challenges and challenges to proving economic value over time continue to hamper broader national commercialization.
South Korea Digital Therapeutics Market Opportunities
The South Korean digital therapeutics market offers opportunities, with rising chronic disease management programs, the rising integration of therapeutic software with connected health ecosystems, the rising need for personalized interventions, and the increasing number of health initiatives supported by employers. Further opportunity exists in outcome-focused care approaches as well as remote care pathways that are scalable and increase engagement without straining health systems.
Healthcare systems identify conditions with unmet treatment needs such as insomnia, ADHD, depression, and diabetes.
Developers create software-based interventions designed to influence measurable health outcomes.
Clinical validation establishes effectiveness, safety, engagement, and treatment relevance.
Products undergo review processes before entering clinical practice environments.
Companies determine whether to pursue prescription-based, direct-to-consumer, or hybrid models.
Stakeholders evaluate temporary reimbursement opportunities, payer engagement, and coverage pathways.
Hospitals, clinics, and healthcare professionals integrate solutions into patient care workflows.
Patients interact through mobile applications, web platforms, wearable-connected systems, and digital treatment programs.
Revenue is generated through subscriptions, reimbursements, enterprise contracts, outcome-based models, or direct purchases.
Clinical outcomes, adherence levels, and utilization patterns shape future expansion decisions.
Why this market matters now
The most important shift is not technological. It is economic.
Digital therapeutics have progressed beyond proving that software can support treatment. The challenge now involves determining who pays, under what conditions, and how evidence translates into reimbursement.
South Korea's healthcare ecosystem is evaluating how digital therapeutics fit within existing care pathways. Temporary reimbursement mechanisms create opportunities but also introduce uncertainty. Companies may achieve adoption without securing long-term payment models. Investors may see utilization growth without corresponding profitability.
For buyers, the risk is misreading adoption signals.
A successful insomnia program may not follow the same commercialization path as an ADHD intervention. A diabetes-focused platform may require entirely different provider engagement and reimbursement strategies than a depression-focused solution.
Understanding these differences is increasingly important as healthcare budgets, technology investments, and regulatory expectations evolve simultaneously.
What matters most when evaluating claims in this market
|
Claim type |
What good proof looks like |
What often goes wrong |
|
Clinical effectiveness |
Measurable patient outcomes and validated studies |
Reliance on engagement metrics alone |
|
Market adoption |
Active utilization within care pathways |
Confusing downloads with adoption |
|
Reimbursement readiness |
Defined coverage pathway and payer engagement |
Assuming pilot programs guarantee reimbursement |
|
Provider acceptance |
Integration into clinical workflows |
Ignoring clinician burden |
|
Commercial scalability |
Repeatable deployment model |
Extrapolating from small trials |
|
Revenue potential |
Sustainable payment mechanisms |
Double counting addressable populations |
The decision lens
Verify what qualifies as digital therapeutics versus broader digital health.
Compare clinical validation, treatment outcomes, and adherence performance.
Examine reimbursement prospects and revenue durability.
Evaluate physician acceptance, patient engagement, and workflow integration.
Assess expansion feasibility across therapeutic areas and channels.
Review regulatory uncertainty, cybersecurity considerations, and compliance requirements.
Identify indicators that support expansion, investment, or partnership decisions.
The contrarian view
Many market assessments assume digital therapeutics adoption automatically translates into commercial success.
That assumption often fails.
A growing user base does not guarantee reimbursement. Strong clinical evidence does not guarantee physician adoption. Temporary payment pathways do not ensure permanent coverage.
Another common mistake is combining wellness applications, telehealth platforms, and digital therapeutics into a single market estimate. This creates inflated opportunity assessments and weak competitive analysis.
A third error involves counting patients multiple times across therapeutic categories, channels, or revenue models.
Serious buyers focus on revenue-generating treatment pathways rather than broad digital health narratives.
Practical implications by stakeholder
Digital Therapeutics Developers
Healthcare Providers
Investors
Payers and Insurers
Hospitals and Health Systems
Strategic Partners
GLOBAL SOUTH KOREA DIGITAL THERAPEUTICS MARKET
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2024 - 2030 |
|
Base Year |
2024 |
|
Forecast Period |
2025 - 2030 |
|
CAGR |
6.1% |
|
Segments Covered |
By Product, Type, Consumption, Distribution Channel and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Welt Co., Ltd., Nunaps Inc., LifeSemantics Corp., Kakao Healthcare, Neurophet Inc. Share&Service Co., Ltd., Huray Positive Ybrain Inc., Emocog Inc., Lunit Inc. |
South Korea Digital Therapeutics Market Segmentation
South Korea Digital Therapeutics Market – By Therapeutic Area
Mental Health & Behavioral Disorders accounted for the market's leading share of 30% in South Korea's digital therapeutics market. There was good uptake in insomnia and depression management, and providers were more likely to incorporate clinically proven digital tools into care.
The Neurological Disorders segment was the fastest-growing segment, accounting for 17% of the market share. Interest in solutions specifically designed for ADHD has increased, as has clinical acceptance and the use of these solutions in other neurobehavioral treatment areas, driving further commercialization potential in the healthcare environment.
South Korea Digital Therapeutics Market – By Delivery Platform
South Korea Digital Therapeutics Market – By Prescription Model
Prescription Digital Therapeutics (PDTx) was the market leader with a 49% market share. Leaders across key therapeutic areas and providers were enabled by physician oversight, increased clinical positioning, and alignment to new reimbursement models.
The fastest-growing segment was hybrid digital therapeutics, accounting for 20% of the market share. Prescription credibility and consumer access allowed for greater patient reach, potential for engagement, and greater commercial flexibility in a changing healthcare landscape.
South Korea Digital Therapeutics Market – By Distribution & Access Channel
South Korea Digital Therapeutics Market – By Revenue Model
South Korea Digital Therapeutics Market– Regional Analysis
The highest market share in South Korea's digital therapeutics market was held by the Seoul capital area, which accounted for 52%. The concentrated presence of major hospitals, sophisticated healthcare facilities, and investments in the digital health sector, coupled with the early adoption of clinically validated therapeutic solutions, contributed to regional leadership.
The top growth region was Busan-Ulsan-Gyeongnam (18%). Market development has been quickly propelled by the expansion of healthcare modernization programs, growing awareness of digital health, growing provider participation, and wider adoption of therapeutic platforms throughout the region.
Latest Market News
On June 16, 2025, Hippo T&C announced that the MFDS has granted Class III approval for BlueKare, the world's first digital therapeutic for depression for over 1 million patients in South Korea. The clearance added to the nation's list of approved digital therapeutics products a second treatment, in addition to the earlier two insomnia-related drugs, giving it a wider slate of approved treatments than it had before.
Dec 24, 2025: BeyondMedicine became the first digital therapeutic to be approved by MFDS as the first in South Korea to be indicated for temporomandibular joint disorder (TMJD). The structured 6-week treatment program was achieved in the form of a smartphone-based therapy, which received class II digital medical device approval.
In industry conversations in Seoul, digital health and biopharma leaders emphasized AI innovations that enable therapeutic development, including the publication of more than 3,000 biomedical papers every day, compared to the 10-15 years invested in conventional drug development. These trends fueled the increasing interest in South Korea in software-based therapeutic interventions.
After being authorized by MFDS, SleepQ is being used for the first time by prescription in South Korea, with a 6-week digital CBT-I program announced by Handok and Welt at Severance Hospital. This launch marked the nation's first-ever commercial prescription event for the insomnia-focused digital therapeutic.
The number of patients receiving Somzz treatment for chronic insomnia has increased at Yongin Severance Hospital, and the treatment is now available at 6 major hospitals and can be used for patients who have symptoms for 3 months or more. The development was a sign of institutionalization of prescription digital therapeutics.
Approximately 11 months after its MFDS approval, Jan 09, 2024, Seoul National University Hospital started to prescribe South Korea's first approved prescribed digital therapeutic (pDT), Somzz. The deployment was a non-pharmacological pathway to insomnia treatment within one of the country's esteemed healthcare institutions.
A digital insomnia therapeutic pilot study with collaboration among 4 clinical and research institutions has yielded positive clinical findings, which have been published in the Journal of Sleep Research. The research was published in a new volume of Volume 33, Issue 1, which is building on a body of evidence for sleep interventions using software.
The academic evaluations of South Korea's digital therapeutics market of last year recognized two digital therapeutics for insomnia, which were approved by MFDS in 2023, marking the first commercial basis for prescription software treatment in the country. Continuous real-world evidence generation and patient adherence were also highlighted as areas of focus in the review.
Key Players
The South Korea Digital Therapeutics Market was valued at approximately USD 163 Million. It is projected to grow at a CAGR of around 19% during the forecast period of 2026–2030, reaching an estimated USD 388.98 Million by 2030.
The major drivers of the South Korea Digital Therapeutics Market include the growing demand for scalable digital treatment delivery, increasing adoption of connected health ecosystems, and the rising focus on personalized healthcare models. Healthcare providers are increasingly utilizing clinically validated software-based therapeutic interventions to improve patient engagement, enhance treatment adherence, and support long-term disease management. Additionally, expanding healthcare digitization, greater interoperability across healthcare systems, increasing awareness among physicians, and the need for efficient chronic disease management solutions continue to accelerate market growth across South Korea.
Mental Health & Behavioral Disorders, Metabolic Disorders, Neurological Disorders, Cardiovascular Diseases, Respiratory Diseases, Musculoskeletal Disorders, Substance Use & Addiction Management, and Others are the segments under the South Korea Digital Therapeutics Market by Therapeutic Area. Mobile Application-Based Therapeutics, Web-Based Therapeutics, Wearable-Integrated Therapeutics, Virtual Reality (VR)-Based Therapeutics, Connected Device-Based Therapeutics, and Others are the segments by Delivery Platform. Prescription Digital Therapeutics (PDTx), Non-Prescription/Direct-to-Consumer Digital Therapeutics, Hybrid Digital Therapeutics, and Others are the segments by Prescription Model. Hospitals & Health Systems, Specialty Clinics, Digital Health Platforms, Employer-Sponsored Programs, Insurance-Linked Programs, Retail & Consumer Health Channels, and Others are the segments by Distribution & Access Channel. One-Time License/Purchase, Subscription-Based Revenue, Reimbursement-Based Revenue, Outcome-Based Revenue, Enterprise Contract Revenue, and Others are the segments by Revenue Model. Seoul Capital Area, Busan-Ulsan-Gyeongnam, Chungcheong, Daegu-Gyeongbuk-Gangwon, and Jeolla & Jeju are the regional segments under the South Korea Digital Therapeutics Market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
